EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Press release // April 11, 2024
- Press release // April 11, 2024
Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
Munich, Germany – Formycon AG (FSE: FYB) and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis®1(Ranibizumab), in Canada and Switzerland. - The launch follows the marketing authorization granted by Health Canada under the trademark RanoptoTM2and Swissmedic under the trademark Ranivisio®3.
- FYB201 was developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV.
- In Canada and Switzerland, FYB201 has been approved for the treatment of age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.